Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liverpool Avastin Dose Response and Retreatment Study
2007-000379-41Phase 4Terminated
- Sponsor
- Royal Liverpool & Broadgreen University Hospitals
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in age-related macular degeneration (AMD), sponsored by Royal Liverpool & Broadgreen University Hospitals. Primary endpoints: Change in best corrected visual acuity at 18 weeks and Change in best corrected visual acuity at 54 weeks. Started Apr 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2007-000379-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000379-41.